Upadacitinib Nitroso impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn's disease.Upadacitinib Nitroso impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Upadacitinib Nitroso impurity 1 CAS NO:NA Chemically represented as (3S,4R)-3-Ethyl-4-(3-nitroso-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide . Synchemia is the leading manufacturing and exporter of Upadacitinib Nitroso impurity 1. We supply Upadacitinib Nitroso impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142884 |
| CAS No | NA |
| Mol.F. | C18H22N2O5 |
| Mol.Wt. | 346.38 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142885 |
| CAS No | NA |
| Mol.F. | C23H28N2O11 |
| Mol.Wt. | 508.48 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142886 |
| CAS No | NA |
| Mol.F. | C12H13N3O6 |
| Mol.Wt. | 295.25 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142887 |
| CAS No | NA |
| Mol.F. | C4H6N6O2 |
| Mol.Wt. | 170.13 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142888 |
| CAS No | NA |
| Mol.F. | C14H11N7O4 |
| Mol.Wt. | 341.29 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142889 |
| CAS No | NA |
| Mol.F. | C26H23N13O8 |
| Mol.Wt. | 645.55g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142890 |
| CAS No | NA |
| Mol.F. | C7H5ClN6O2 |
| Mol.Wt. | 240.61g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142891 |
| CAS No | NA |
| Mol.F. | C19H18N8O7 |
| Mol.Wt. | 470.40 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142892 |
| CAS No | NA |
| Mol.F. | C19H18N8O7 |
| Mol.Wt. | 470.40 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142893 |
| CAS No | NA |
| Mol.F. | C31H30N10O11 |
| Mol.Wt. | 718.64 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142894 |
| CAS No | NA |
| Mol.F. | C23H23N13O7 |
| Mol.Wt. | 593.52 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142895 |
| CAS No | NA |
| Mol.F. | C19H16N8O7 |
| Mol.Wt. | 468.39 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142896 |
| CAS No | NA |
| Mol.F. | C30H29ClN10O9 |
| Mol.Wt. | 709.07 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142897 |
| CAS No | NA |
| Mol.F. | C21H26N8O7 |
| Mol.Wt. | 502.49 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142898 |
| CAS No | NA |
| Mol.F. | C19H18N8O7 |
| Mol.Wt. | 470.40 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142899 |
| CAS No | NA |
| Mol.F. | C15H17N7O4 |
| Mol.Wt. | 359.35 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |